This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Oragenics, Inc. (OTCQB: OGEN) (OTCBB: OGEN) (the “Company”), a world leader in oral care probiotics, today announced that the Company has entered into a new three year contract agreement with Organic Wave, Inc. Under the terms of the agreement, Organic Wave will be the exclusive distributor of Oragenics’ oral care probiotics for pets in Japan under the Evora name as well as a private label brand. The pet product will contain
ProBiora3®; Oragenics’ patented proprietary blend of three probiotics specifically designed for improved oral health.
Organic Wave operates as a subsidiary of Orthomolecular Nutrition Laboratory which was established in 1985 to practice Orthomolecular Medical Nutrition and to spread the knowledge gained to the general public throughout Japan. The laboratory offers study groups, seminars and lectures focusing on various topics. It provides updated scientific news and information for members, and offers courses for medical doctors who are implementing a nutritional approach in their medical field.
“The completion of the agreement with Organic Wave gives Oragenics a gateway to the pet market in Japan for the oral care probiotic product
EvoraPet. As in the US, the Japanese not only value their companion dogs and cats but they understand the importance of good oral health to the overall health of humans and pets,
” stated John N.Bonfiglio PhD, President and CEO of Oragenics.
About Oragenics, Inc.
Oragenics, Inc. is focused on becoming the world leader in probiotics for oral health for humans and pets and in novel antibiotics against infectious disease. Oragenics, Inc. develops, markets and sells proprietary probiotics specifically designed to enhance oral health for humans and pets, under the brand names
ProBiora® in over 13 countries worldwide. Oragenics, Inc. has established an exclusive worldwide channel collaboration for lantibiotics, a novel class of broad spectrum antibiotics, with Intrexon Corporation, a synthetic biology company.
For more information, visit
www.oragenics.com. Follow Oragenics on
Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect the Company’s current views with respect to future events and financial performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to our ability to raise additional capital to sustain our operations beyond June 30, 2012 and those set forth in our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the U.S. Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.For more information visit www.oragenics.com.